title: [Unresectable pancreatic cancer in the Hokuriku area].
abstract: To clarify the diagnosis and treatment for unresectable pancreatic cancer from April 2001 when gemcitabine was released, we conduct a retrospective survey in the Hokuriku area. We analyzed clinical data of 254 patients. Seventy-two percent of the patients was treated by any method, and 90.7% of those were treated with a protocol including gemcitabine. Gemcitabine was administered a standard protocol (1000 mg/m(2) for 3 consecutive weeks with one week rest) in 62.2% patients, and dose of gemcitabine was reduced or schedule was changed in others. The median survival time was 8.2 months in the therapy group, and were is no differences between gemcitabine monotherapy, multi-drug therapy including gemcitabine and radiation combining gemcitabine in survival time. Multivariable analysis clarify patient's age, performance status, ascites, pleural effusion, and any therapy were prognostic factors. This investigation revealed chemotherapy for unresectable pancreatic cancer with gemcitabine have been spread around the Hokuriku area, in addition various ways have been tried.
authors.affiliation: Department of Gastroenterology, Kanazawa University Graduate School of Medicine.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Terashima
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Yamashita
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Arai
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Iida
authors.forename: Kaheita
authors.initials: K
authors.lastname: Kakinoki
authors.forename: Kazuya
authors.initials: K
authors.lastname: Kitamura
authors.forename: Takashi
authors.initials: T
authors.lastname: Kagaya
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Sakai
authors.forename: Eishiro
authors.initials: E
authors.lastname: Mizukosi
authors.forename: Akito
authors.initials: A
authors.lastname: Sakai
authors.forename: Yasunari
authors.initials: Y
authors.lastname: Nakamoto
authors.forename: Masao
authors.initials: M
authors.lastname: Honda
authors.forename: Syuuichi
authors.initials: S
authors.lastname: Kaneko
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D015999:Multivariate Analysis; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D015996:Survival Rate; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D000093542:Gemcitabine